Evaluation of efficacy of derma roller sizes vs topical application for administration of QR678® anti-hair loss formulation in the clinical assessment of androgenetic alopecia
Background and Scientific Context
In clinical dermatology practice, multiple delivery methods are used to support scalp-based formulations, particularly in the context of androgenetic alopecia. Topical application remains the most commonly used approach due to ease of use and patient familiarity. Dermaroller-assisted delivery, which involves controlled micro-injury to the scalp, has also been explored as a method to enhance localized scalp exposure and procedural penetration.
Comparative documentation of different delivery techniques provides insight into procedural considerations, tolerability, and observable hair and scalp parameters under routine practice conditions. This study presents descriptive clinical documentation of patients with androgenetic alopecia receiving QR678 through two different delivery approaches—dermaroller-assisted application and topical application—without attributing causality or clinical outcomes to either method.
Study Design and Clinical Framework
The study was conducted as a prospective clinical evaluation involving male and female patients diagnosed with androgenetic alopecia based on established clinical classification systems. Participants were enrolled following predefined inclusion criteria and were allocated into two groups based on the delivery approach used.
One group received QR678 administered using a dermaroller-assisted technique, involving controlled microneedling of the scalp followed by localized application. The second group received QR678 via topical application according to a standardized protocol. All procedures were performed under dermatological supervision.
The study followed an open-label design without randomization, blinding, or placebo control. Baseline assessments were conducted prior to initiation of either delivery approach, with follow-up evaluations performed at scheduled intervals over the observation period.
The objective of the study was to document hair and scalp parameters observed during use of two different delivery techniques in routine clinical practice.
Assessment Parameters
Clinical documentation was performed using commonly employed dermatological assessment tools, including:
- Hair pull testing to record active hair shedding at the time of examination
- Trichoscopic and videomicroscopic evaluation to document hair density, follicular distribution, and hair shaft characteristics
- Global photographic assessment to visually record scalp appearance across defined regions
- Patient-reported observations recorded during structured clinical consultations
These parameters were recorded descriptively and used to support longitudinal documentation within each group across study visits.
Observational Findings
Across successive evaluations, clinicians documented changes noted in hair shedding patterns, scalp appearance, and hair shaft characteristics within each delivery group. Observations were recorded without assigning causality to the delivery technique used and without attributing observed changes to procedural effectiveness.
Trichoscopic and photographic documentation provided visual records of hair and scalp parameters over time within individual patients. Variability in observations was noted across participants, reflecting known differences in hair cycle phases, scalp characteristics, and individual biological response.
Patient-reported observations reflected subjective perceptions related to hair appearance, scalp feel, and procedural experience. These reports were documented descriptively and were not interpreted as indicators of clinical benefit or comparative outcome.
Procedural and Tolerability Observations
Procedural tolerability was monitored throughout the study duration. In the dermaroller-assisted group, observations included transient scalp sensations associated with microneedling. In the topical application group, observations were limited to localized scalp sensations associated with application.
Across both groups, reported observations were mild and temporary. No systemic adverse events were reported during the observation period. No participants discontinued the study due to tolerability-related concerns.
Procedural differences between dermaroller-assisted and topical application were documented as part of routine clinical observation, without interpretation regarding preference, effectiveness, or long-term impact.
Scope, Limitations, and Research Relevance
The study is subject to limitations inherent to observational clinical evaluations, including absence of randomization, lack of blinding, and reliance on descriptive documentation. The study does not establish therapeutic efficacy, comparative advantage, or long-term outcomes associated with either delivery approach.
Within these constraints, the paper contributes structured clinical documentation of hair and scalp parameters observed with two different methods of QR678 administration. The findings may serve as reference material for clinicians reviewing procedural considerations and delivery approaches under routine dermatology practice conditions.
Disclaimer:
The research papers and clinical articles referenced on this website are peer-reviewed scientific publications authored by qualified medical professionals and represent the observations and conclusions of the respective authors, based on their individual clinical research.
These clinical references are provided for informational and educational purposes and should not be interpreted as promotional claims or outcome guarantees by QR678®. Consumers are advised to consult a qualified healthcare professional for medical interpretation or hair- or scalp-related concerns.
QR678®: SCIENCE Backed Research & Development Proprietary Product Technology
The QR678® research & development platform technology is a proprietary first-in-class technology. This science backed technology is giving rise to multiple products that arrest hair fall and address the thickness, density of hair follicles leading to greater coverage in hair loss. This R&D technology deals with multiple human hair growth related growth factors that are naturally present in our scalp making products derived from these completely natural. Research on this platform technology has resulted in this being awarded USA & Indian patents and has led to over 16+ clinical research papers being published with products derived from this unique technology. The hair growth factors penetrate deep into the scalp and provide nourishment to the scale. Unlike other treatments that contains harmful medication, products derived from QR678® are almost completely devoid of side effects.
HOW DOES IT WORK?
Benefits of choosing QR678®
QR678® ADVANTAGES
(Derived From Plants)
Quick & Effective (Single
Session in 10 Minutes)
Non Surgical
Success Rate
13+ Published Researched Clinical Trials Demonstrating Efficacy
LIFE CHANGING RESULTS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
25 year old female from alopecia areata, was also diagnosed with hypothyroid. She achieved impressive results with QR678, a completely steroid-off treatment.
PRE TREATMENT
POST 6 SESSIONS
39 year old male suffering from male pattern hair loss for 15 years gained a significant amount of hair with QR678
MEDIA INTERVIEWS
TESTIMONIALS
HIGHLIGHTS IN MEDICAL CONFERENCES
CUTICON – December 2023
Dazzling moments at Cuticon 2023, Gujarat! QR678 took centre stage, earning accolades from top medical professionals.
QR678 made it’s presence felt at FADS (Face Aesthetics Dermatologists Society), the 7th International Conference held at Goa. Renowned dermatologists got QR678 Neo administered and shared their positive experience.
QR678® drew attention with an enlightening session and live demonstration at CDCON 2022 – a platform to challenge changing practices along the lines of Exploration and Innovation.
GLOBAL PRESENCE
OUR PARTNERS
FAQ'S
How is QR678® better than other hair fall treatments?
QR678® is a mixture of natural growth factors that are already present in the scalp and therefore it is completely safe to use on everybody. It has the right concentration of specific hair growth factors and QR678® does not have any side effects, is performed as an outpatient procedure and the results are visible within eight weeks of starting the treatment. You can listen for yourself what the patients say about QR678® hair fall treatment https://www.youtube.com/watch?v=pIvjpQgSsrc
How often do I need to repeat QR678® treatment?
QR678® injections are administered in 8-12 sessions in about 3-4 weeks apart. The results are visible after few weeks. Once you have achieved the desired results the injections need not be repeated unless the hair fall starts again. This is because QR678® make the hair follicles healthy. Get to know more about why QR678® is highly effective in treating hair fall and increasing hair growth. http://www.qr678.in/
What precautions should I take after QR678® treatment?
QR678® is a completely safe treatment without side effects and you can go about your daily routine after the sessions. The only care you need to take is to use a gentle shampoo not before the next day of the treatment and avoid scratching and rubbing the treating area. If you have any other problem then consult your dermatologist. https://www.youtube.com/watch?v=LNm2z3EGLxg
Can QR678® be used after hair transplant?
Yes, using QR678® after hair transplant produces very successful results. QR678® gives faster density and reduces the catagen loss of transplanted hair. The growth factors in QR678® Neo help in faster healing and activate the dormant follicles and thus
- Increase the viability of hair follicles
- Improve healing and repairing of tissue process
- Strengthen the inactive hair follicles and stimulate hair growth
- Improves the health of existing hair and they will become fuller and stronger
QR678® can be given in multiple treatment sessions after three to four weeks after successful hair transplant surgery. QR678® can also be used before the hair transplant surgery to reduce the area of transplant and improve the results.
How is QR678® better than PRP and stem cell hair fall treatment?
QR678® is a relatively new treatment for hair fall and hair regrowth but in the short time of its invention QR678® has proven to be more effective than PRP and stem cell treatment for reducing hair fall. QR678® produces longer lasting and better results and is completely safe and without any side effects. QR678® can help treat and rogenetic alopecia, female pattern hair loss, and hair loss because of chemotherapy, seborrheic dermatitis, and alopecia areata.
PRP and stem cell on the other hand do not have the specific concentration of required growth factors, they lack standardisation in terms of treatment protocols and preparation of the solution injected and lack good quality studies to prove their benefits. produce guaranteed results and can cause tightness and tenderness in scalp,
scar tissue formation, calcification of the injected points, and formation of scar tissues. Both processes are still under investigation and their results are still awaiting confirmation. Dr Rinky Kapoor of The Esthetic Clinics explains the difference between QR678® and stem cell here: https://www.youtube.com/watch?v=wgNihm8ciu4 and
Can genetic hair loss be treated?
Yes genetic hair loss can be treated if the treatment is started in time. Heredity hair loss usually runs in the family and can affect both men and women. If you too have a close elder relative who lost his or hair in a patterned baldness then you should keep a close eye on your hair too. Hereditary hair loss usually happens in a pattern; M or W shaped in men and along the hair part in women. See the doctor immediately if you suffer from hair loss. There are many common and successful treatments available for genetic hair loss which include
- Topical and oral medications: These include Minoxidil topical lotion and Finasteride tablets.
- Hair transplantation using FUT and FUE methods.
- Nutritional supplements: Your physician might also suggest some hair supplements that can help arrest hair fall. Dietary supplements containing Vitamin A, C, and Biotin, zinc, and iron can also help control hair fall caused because of genetics.
Treatment option for Chemotherapy induced Alopecia?
Alopecia post chemotherapy is a very common consequence of cancer treatments and therapies and it is often the most psychologically and socially devastating side effect. Many patients shy away from the treatments because of fear of hair fall and hair loss. However, in most cases, such alopecia is reversible but the recovery takes several months and even up to a year. Some basic latest treatment methods will speed up the healing:
- Scalp Cooling: This is a FDA approved method for patients suffering from breast cancer. Scalp cooling or hypothermia results in constriction of the blood vessels in the scalp, which in turn leads to reduced delivery of chemotherapy to the hair. Scalp cooling devices consist of cooling unit that circulate the coolant on the scalp. This is done about 30 minutes before the start of chemotherapy. Patients can feel some mild discomfort, nausea, and dry skin because of scalp cooling.
- Topical Minoxidil: Minoxidil helps by increasing the blood flow to the hair follicle thereby preventing miniaturization of hair follicle.
- QR678® hair regrowth treatment: QR678® is a FDA approved, completely safe hair regrowth treatment that has no side effects or causes any discomfort to the patient. Clinical trials have proved QR678 to be effective in treatment of chemotherapy induced alopecia in both men and women. The results of QR678® last lifelong.